CytomX Therapeutics, Inc. (CTMX) stock intrinsic value fair value estimate & owner earnings analysis

CytomX Therapeutics is a clinical-stage biotechnology company. Its revenue comes from research collaborations with partners rather than from selling an approved medicine, and its own spending is on clinical development and research. In January 2025 it announced a restructuring that cut about 40% of its workforce and focused spending on Varseta-M and CX-801, plus the work supporting its research collaborations. How we measure earnings. We start from cash generated by operations, remove the swings from working capital (mainly the payments partners made upfront and the company later recognises as revenue), subtract stock-based compensation as a real cost, and subtract only the part of capital spending needed to maintain the business. Capital spending is tiny (about $0.2 million in 2025). On this basis, owner earnings per share over the last ten years were negative in nine years, ranging from about -$2.23 to -$0.03 per share, and positive in only one, 2024 (about +$0.38). The 2024 figure reflects revenue of $138.1 million, much of it recognition of upfront payments received in earlier years (deferred revenue fell $118.3 million that year), not new cash. In 2025, revenue was $76.2 million, deferred revenue fell a further $65.6 million, and cash used in operations was $75.6 million; on our measure owner earnings were about -$13.5 million, or about -$0.10 per share. Because the business has not produced positive owner earnings on a repeatable basis, the median over any reasonable window is negative. What we credit in each case. A value has to come from something already signed, under way, or repeatedly demonstrated. Cash on the balance sheet is not added on top of the cases, and debt is not subtracted, because our approach values the stream of owner earnings itself. On that basis we found nothing that meets the bar. Clinical programs such as Varseta-M and CX-801 have not yet produced approved products or a proven, repeated record of earnings, and we do not credit results that have not happened. Partner milestone payments (for example a $5.0 million milestone collected in March 2025) are real but small and irregular relative to annual cash costs, and we did not find a contracted stream large enough to outweigh those costs. Bear case: about $0 per share. Spending continues to exceed cash inflows, the company must raise more equity to keep operating, and existing shareholders are diluted. The filing states that existing capital resources are expected to fund planned operations into the second quarter of 2027 and that additional capital will be needed. In 2025 the company sold new shares and pre-funded warrants (net proceeds of about $110 million) and its weighted diluted share count rose to about 137.9 million from about 84.7 million in 2024. Base case: about $0 per share. Owner earnings stay negative; nothing we can name and evidence turns them positive. Bull case: about $0 per share. Even if the company's programs and partnerships progress well, we could not point to a signed contract or demonstrated record that produces positive owner earnings, so we do not assign value. If a program did reach approval or a partner paid large milestones, that would be new information and would change this analysis. The shares are therefore not valued at a positive amount, and this method produces no positive margin-of-safety price. Note that the company held $137.1 million of cash, cash equivalents and short-term investments at December 31, 2025 against an accumulated deficit of $711.9 million; that cash funds the operating losses, and we do not treat it as extra value per share. In February 2025 the company received a Nasdaq notice that its share price had been below the $1.00 minimum bid requirement; it later regained compliance, but the filing notes it cannot assure that compliance will be maintained. What would make this wrong: a clinical program reaching approval, or partners paying milestones and licence fees that exceed the company's cash costs on a recurring basis. Those outcomes are possible but are not something the filings yet show as contracted or demonstrated.